Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 6-6 (IGHD6-6) is one of several D (diversity) gene segments present in the immunoglobulin heavy chain locus (IGH) on human chromosome 14. During B cell development, the antibody heavy chain variable region is generated by somatic recombination that joins a random V (variable), D (diversity), and J (joining) segment. The D segments, such as IGHD6-6, contribute to the hypervariable third complementarity-determining region (CDR3) of the heavy chain, which is critical for antigen specificity and binding diversity[1][3]. IGHD6-6 and other D segments are not translated as standalone proteins or direct cellular targets but form essential building blocks in the genetic generation of antibody diversity. IGHD6-6 is not classified as a therapeutic target, receptor, or enzyme, nor is it directly implicated as a standalone biomarker, drug-interacting molecule, or disease-associated gene product. Its function is restricted to gene rearrangement events that, in aggregate, result in the extensive library of potential antibodies the adaptive immune system can produce[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 6-6 gene segment (IGHD6-6).